Audited Supplier
D-sung Dolutegravir
Yes
Customized
GMP, HSE, ISO 9001, USP, BP
Elderly, Children, Adult
Powder
>99%
Dolutegravir
Dolutegravir Powder
White Powder
White
Pharmaceutical Grade
HPLC 99%
Pharmaceutical; Anti-Viral
COA
HPLC
2 Years
1051375-16-6
C20h19f2n3o5
419.38
668.958 °c at 760 Mmhg
1.53
D-sung
Negotiable
99%
Shaanxi Xi'an
Product Description
Raw Material CAS 1051375-16-6 Dolutegravir 99% Purity Dolutegravir Pharmaceutical Intermediate Dolutegravir
| Product name | Dolutegravir |
| Appearance | White powder |
| CAS NO. | 1051375-16-6 |
| MF | C20H19F2N3O5 |
| MW | 419.38 |
Dolutegravir (Dolutegravir, Tivicay) is a new anti-AIDS drug developed by the British pharmaceutical giant GlaxoSmithKline (GSK) and Japan's Shionogi Pharmaceutical Company (Shionogi). In July 2012, GlaxoSmithKline Pharmaceuticals and Shionoyoshi Pharmaceuticals announced the results of the Phase III clinical trial of the new AIDS drug Dolutegravir. After receiving dolutegravir and two other old-version AIDS drugs for 48 weeks, 88% of the patients' bodies The virus was successfully suppressed, and Gilead Sciences' three-in-one oral drug Atripla (Efavirenz/Emtricitabine/TenofovirDisoproxilFumarate) After that, 81% of the virus in the patient's body was suppressed. It can be seen that the dolutegravir drug of GlaxoSmithKline is slightly better. According to the researchers, in the comparison trial, due to the side effects of the drug, 10% of the patients eventually stopped taking Gilead's Atripla drug, but only 2% of the patients stopped taking GlaxoSmithKline's dolutegravir. Drugs, it can be seen that the safety of GlaxoSmithKline dolutegravir is slightly higher.Dulutvir sodium salt is a second-generation HIV-1 integrase chain transfer inhibitor. Dulutvir sodium is currently in phase III clinical trials for the treatment of HIV infection. It has been shown that Dulutvir Chemicalbook sodium salt can effectively inhibit HIV replication in cells infected with inactivated PHIV lentiviral vectors (such as peripheral blood mononuclear cells (PBMC), MT-4 cells and CIP4 cells).
Dulutvir sodium salt is a second-generation HIV-1 integrase chain transfer inhibitor. Dulutvir sodium is currently in phase III clinical trials for the treatment of HIV infection. It has been shown that Dulutvir Chemicalbook sodium salt can effectively inhibit HIV replication in cells infected with inactivated PHIV lentiviral vectors (such as peripheral blood mononuclear cells (PBMC), MT-4 cells and CIP4 cells).
